Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 04 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a press release regarding an exclusive licensing and supply agreement with Synthon for Ozanimod Capsules, a generic version of ZEPOSIA, intended for the U.S. market. The agreement outlines that Synthon will handle regulatory approval and manufacturing, while Zydus will manage commercialization in the U.S. This collaboration aims to enhance access to essential medicines for patients with relapsing forms of multiple sclerosis.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 04, 2025, titled "Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases